FierceBiotech21h
AnaptysBio scraps atopic dermatitis asset after antibody fails to meet all endpoints in ph. 2
AnaptysBio is dropping its atopic dermatitis (AD) drug candidate after the compound failed to reduce eczema area and itch ...
clinicaltrialsarena3h
AnaptysBio’s atopic dermatitis trial of BTLA agonist misses endpoints
AnaptysBio has reported that the ARISE-AD trial of ANB032, for treating moderate-to-severe atopic dermatitis failed to meet both endpoints.
Anaptys Announces Phase 2b Trial of ANB032, a BTLA Agonist, Did Not Meet Primary or Secondary Endpoints in Atopic Dermatitis
ANB032 was well tolerated across all doses with no safety signals observedAD trial and all further investment in ANB032 will be ...
Fintel on MSN12h
HC Wainwright & Co. Downgrades AnaptysBio (ANAB)
Fintel reports that on December 11, 2024, HC Wainwright & Co. downgraded their outlook for AnaptysBio (NasdaqGS:ANAB) from ...
Seeking Alpha20d
AnaptysBio: An Immunology Pipeline-In-A-Pill Company Worth Watching
AnaptysBio has been able to use its technology to develop 2 compelling lead drug candidates. Their pipeline has 2 key readouts in December 2024 and February 2025 worth monitoring. The near-term ...
AnaptysBio announces Phase 2b trial of ANB032 did not meet primary endpoint
AnaptysBio (ANAB) announced that investigational ANB032, a BTLA agonist, did not meet the primary and secondary endpoints in any of the doses ...
Fintel on MSN9d
BTIG Downgrades AnaptysBio (ANAB)
Fintel reports that on December 2, 2024, BTIG downgraded their outlook for AnaptysBio (NasdaqGS:ANAB) from Buy to Neutral.
Key Takeaways From AnaptysBio Analyst Ratings
Return on Equity (ROE): AnaptysBio's ROE is below industry averages, indicating potential challenges in efficiently utilizing ...
Hold Rating on AnaptysBio Amidst Setbacks in ANB032 and Rosnilimab Efficacy
In a report released today, Emily Bodnar from H.C. Wainwright downgraded AnaptysBio (ANAB – Research Report) to a Hold, with a price target of ...